Annual Total Liabilities
$3.53 M
-$372.20 K-9.54%
31 December 2023
Summary:
Inhibikase Therapeutics annual total liabilities is currently $3.53 million, with the most recent change of -$372.20 thousand (-9.54%) on 31 December 2023. During the last 3 years, it has fallen by -$1.47 million (-29.40%). IKT annual total liabilities is now -29.40% below its all-time high of $5.00 million, reached on 31 December 2020.IKT Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$4.91 M
+$1.18 M+31.56%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly total liabilities is currently $4.91 million, with the most recent change of +$1.18 million (+31.56%) on 30 September 2024. Over the past year, it has increased by +$2.04 million (+71.42%). IKT quarterly total liabilities is now -25.52% below its all-time high of $6.59 million, reached on 30 September 2020.IKT Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -9.5% | +71.4% |
| 3 y3 years | -29.4% | +81.2% |
| 5 y5 years | -2.6% | - |
IKT Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -29.4% | at low | at high | +81.2% |
| 5 y | 5 years | -29.4% | at low | -25.5% | +127.0% |
| alltime | all time | -29.4% | at low | -25.5% | +127.0% |
Inhibikase Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.91 M(+31.6%) |
| June 2024 | - | $3.73 M(-13.1%) |
| Mar 2024 | - | $4.29 M(+21.6%) |
| Dec 2023 | $3.53 M(-9.5%) | $3.53 M(+23.3%) |
| Sept 2023 | - | $2.86 M(-0.7%) |
| June 2023 | - | $2.88 M(+1.4%) |
| Mar 2023 | - | $2.84 M(-27.1%) |
| Dec 2022 | $3.90 M | $3.90 M(+13.2%) |
| Sept 2022 | - | $3.44 M(-23.3%) |
| June 2022 | - | $4.49 M(+2.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $4.38 M(+8.0%) |
| Dec 2021 | $4.05 M(-18.9%) | $4.05 M(+49.7%) |
| Sept 2021 | - | $2.71 M(+25.3%) |
| June 2021 | - | $2.16 M(-43.7%) |
| Mar 2021 | - | $3.84 M(-23.2%) |
| Dec 2020 | $5.00 M(+10.4%) | $5.00 M(-24.1%) |
| Sept 2020 | - | $6.59 M(+26.8%) |
| June 2020 | - | $5.20 M(+9.7%) |
| Mar 2020 | - | $4.74 M(+4.7%) |
| Dec 2019 | $4.53 M(+24.9%) | $4.53 M |
| Dec 2018 | $3.62 M | - |
FAQ
- What is Inhibikase Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual total liabilities year-on-year change?
- What is Inhibikase Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly total liabilities year-on-year change?
What is Inhibikase Therapeutics annual total liabilities?
The current annual total liabilities of IKT is $3.53 M
What is the all time high annual total liabilities for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual total liabilities is $5.00 M
What is Inhibikase Therapeutics annual total liabilities year-on-year change?
Over the past year, IKT annual total liabilities has changed by -$372.20 K (-9.54%)
What is Inhibikase Therapeutics quarterly total liabilities?
The current quarterly total liabilities of IKT is $4.91 M
What is the all time high quarterly total liabilities for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly total liabilities is $6.59 M
What is Inhibikase Therapeutics quarterly total liabilities year-on-year change?
Over the past year, IKT quarterly total liabilities has changed by +$2.04 M (+71.42%)